Pfizer’s $5.4B GBT Bet Pays Off with Promising Phase II Data for Oxbryta Successor

By /

Patients treated with the investigational sickle cell therapy saw an increase in hemoglobin levels and improved red blood cell parameters.

Scroll to Top